Meditrial MDR DIVERSITY Germany Clinical Trials
The medical device regulation EU 2017/745 allows Member States some adjustments for local implementation.
If you sponsor a trial in Germany, you must learn what are the new ordinances and guidelines for the implementation of the MDR.
The Authorities will expect that you follow the new procedures by the deadline of May 26, 2021.
You will be expected to amend your study and train the Investigators to meet the new German requirements.
FREQUENT QUESTIONS
• Do I need to compile the new reporting form for all previous events?
No. BfArM has all records of prior events. Only submit events occurring after 26 May
• Should the quarterly Report only contain SAEs from Germany?
No. You should include all reportable SAEs in your study.
ARE YOU READY?
As the implementation of the EU MDR has already proven to be a complex and challenging process, it is important to ensure you are going in the right direction. For example, Germany has introduced specific rules with regards to investigator safety reporting.
CONTACT US NOW
Partnering with Meditrial will allow you a quick and rapid upgrade of your trials to the MDR.
• All of your questions will be answered by regulatory experts in simplified language
• You will have access to dedicated tutorials and educational materials
• Our medical writers will provide assistance with the document revisions
• Our clinical team will help to implement the revised study.
Meditrial will not only ensure your medical device complies with the MDR and Member States requirements, but that you ultimately achieve market approval.
To learn more, visit: www.meditrial.net
Table of Contents
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
The contribution of patient associations in clinical trials
Historically, patient organizations have had the primary purpose of supporting the communities they represented. Today, this remains a crucial function, but modes have changed, as has the role that associations and patients themselves take on [...]
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
